Press Releases Items Per Page 102550 Year None2020201920182017201620152014 08-05-2020 Daré Bioscience to Host Second Quarter 2020 Financial Results and Company Update Conference Call and Webcast on August 12, 2020 07-27-2020 Daré Bioscience Announces Initiation of Phase 1 Clinical Trial of DARE-HRT1, a Novel Intravaginal Ring Designed to Deliver Non-oral, Bio-identical Hormone Therapy for the Treatment of Menopausal Symptoms 06-24-2020 Daré Bioscience Announces Publication of a Peer-Reviewed Journal Article Supporting the Use of the Postcoital Test Study as a Predictor of Contraceptive Effectiveness by Biology of Reproduction 06-17-2020 Daré Bioscience Announces Initiation of Pivotal Phase 3 Study of DARE-BV1 in Patients with Bacterial Vaginosis 06-15-2020 Daré Bioscience Announces Receipt of $1.5 Million Under the Current Grant Supplement Award for Continued Development of User-Controlled Long Acting Reversible Contraceptive 06-04-2020 Daré Bioscience Announces Participation in BIO Digital 2020 05-14-2020 Daré Bioscience Reports First Quarter 2020 Financial Results and Provides Company Update 05-11-2020 Daré Bioscience and Health Decisions Form Strategic Partnership to Accelerate the Development of Daré’s Novel Pipeline of Women’s Health Programs 05-07-2020 Daré Bioscience to Host First Quarter 2020 Financial Results and Company Update Conference Call and Webcast on May 14, 2020 04-28-2020 Daré Bioscience CEO to Participate in Maxim Group’s Infectious Disease Virtual Conference Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 22
08-05-2020 Daré Bioscience to Host Second Quarter 2020 Financial Results and Company Update Conference Call and Webcast on August 12, 2020
07-27-2020 Daré Bioscience Announces Initiation of Phase 1 Clinical Trial of DARE-HRT1, a Novel Intravaginal Ring Designed to Deliver Non-oral, Bio-identical Hormone Therapy for the Treatment of Menopausal Symptoms
06-24-2020 Daré Bioscience Announces Publication of a Peer-Reviewed Journal Article Supporting the Use of the Postcoital Test Study as a Predictor of Contraceptive Effectiveness by Biology of Reproduction
06-17-2020 Daré Bioscience Announces Initiation of Pivotal Phase 3 Study of DARE-BV1 in Patients with Bacterial Vaginosis
06-15-2020 Daré Bioscience Announces Receipt of $1.5 Million Under the Current Grant Supplement Award for Continued Development of User-Controlled Long Acting Reversible Contraceptive
05-11-2020 Daré Bioscience and Health Decisions Form Strategic Partnership to Accelerate the Development of Daré’s Novel Pipeline of Women’s Health Programs
05-07-2020 Daré Bioscience to Host First Quarter 2020 Financial Results and Company Update Conference Call and Webcast on May 14, 2020
